Status:
COMPLETED
A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Parkinson's Disease
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
This study is to determine if Tyramine has any side effects on patients receiving 0.5mg, 1mg of Rasagiline or Placebo
Eligibility Criteria
Inclusion
- Men and women with idiopathic Parkinson's disease (PD) who have met inclusion criteria for PRESTO, and have completed the 26-week PRESTO study. The subject should be available to participate in the sub-study immediately following the last PRESTO visit (same day). Subjects must continue PRESTO study drug until the morning of the Tyramine Sub-Study.
- Subjects must provide separate informed consent to participate in the Tyramine Sub-Study.
Exclusion
- Subjects must not have a history of intracranial aneurysm or stroke.
- Subjects should not have uncontrolled hypertension, defined as systolic pressure \> 160 mmHg, or diastolic pressure \> 90 mmHg.
Key Trial Info
Start Date :
October 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2003
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00203125
Start Date
October 1 2000
End Date
January 1 2003
Last Update
April 12 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.